Intervacc is trading at €0.04, down 27.30% today, as the stock faces significant selling pressure without a confirmed company-specific catalyst.
- No immediate corporate announcements or regulatory filings were identified to explain the sharp November 6 move, and market coverage remains limited.
- The decline occurs alongside broader biotech sector weakness, with the XBI index down 5.19%, which may be contributing to the downward trend.
- The most recent company update was a November 3 report regarding Strangvac, though it does not provide a clear explanation for the current price action.